In Case You Missed It: Top 10 "Gray Sheet" Stories In May
This article was originally published in The Gray Sheet
"Gray Sheet" stories that captured the most Web traffic last month centered on Boston Scientific's application of postmarket risk management, a rise in human factors questions for combo products, and guidance mandates in the "21st Century Cures" bill.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.